Abstract
Big Data and Parkinson’s Disease - from Understanding of Disease to Personalised Medicine
Highlights
Parkinson’s Progression Markers Initiative (PPMI), sponsored by the Michael J Fox Foundation for Parkinson’s Research, is a multi-centre collaborative observational study that collects clinical, behavioural, imaging, genetic and biological sampling from cohorts of significant interest - and these include de novo Parkinson’s Disease (PD) patients and participants at high risk of developing PD
Parkinson’s Progression Markers Initiative (PPMI), sponsored by the Michael J Fox Foundation for Parkinson’s Research, is a multi-centre collaborative observational study that collects clinical, behavioural, imaging, genetic and biological sampling from cohorts of significant interest - and these include de novo PD patients and participants at high risk of developing PD. It provides a standardised and longitudinal PD database and biorepository which are open to the wider scientific community
Many statistical models do not account for possible interdependence of the multiple parameters being sampled and this could lead to reduction of the degree of freedom and violation of some statistical principles
Summary
Parkinson’s Progression Markers Initiative (PPMI), sponsored by the Michael J Fox Foundation for Parkinson’s Research, is a multi-centre collaborative observational study that collects clinical, behavioural, imaging, genetic and biological sampling from cohorts of significant interest - and these include de novo PD patients and participants at high risk of developing PD. Genome Wide Association Studies (GWAS) involving thousands of patients have successfully identified susceptibility genetic loci for Parkinson’s Disease (PD) (Simon-Sanchez et al, 2009).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have